Third quarter performance update
17 February 2023
Third Quarter Performance Update
Blis Technologies Limited (Blis) delivers revenue growth of 24% and a positive EBITDA
result for the third quarter ending 31 Dec 2022 (unaudited).
Revenue for the quarter
[1]
was $2.9m, an increase of $0.6m compared with the same
period last year
[2]
. EBITDA profit for the quarter
[1]
was $0.3m.
“The continued recovery of our European ingredient business has seen sales volumes
return to the pre-covid levels of FY20. Revenue growth is also being delivered in the
New Zealand based retail channel (incl Daigou) and online sales through Amazon USA.
This growth along with refocused market investment has returned us to a path for
sustainable profitability, with a positive EBITDA forecast for the second half year.” said
Brian Watson CEO.
Revenue for the nine months to 31 December 2022 was $7.2m up 15% on the same
period last year, EBITDA loss for this same nine month period is $0.9m, which includes
one off costs associated with the strategy reset of $0.3. This is a solid improvement on
the $1.9m EBITDA loss in the same period last year.
Based on our latest customer sales forecasts and market feedback, guidance is for full
year revenue to be between $9.5m and $9.8m, with an EBITDA deficit in the range of
$1.0m to $1.2m.
[1]
The three months ended 31 December 2022
[2]
The three months ended 31 December 2021
Ends
For further information, please contact:
Brian Watson
CEO
+64 27 705 9133
About Blis Technologies Ltd
Delivering proven health benefits through evidence-based, advanced probiotics
Blis Technologies is an NZX-listed manufacturer of advanced probiotic strains that go beyond the gut.
Combining innovation with evidence-based research and the highest quality production controls enables
the delivery of probiotic solutions for specific health targets including throat health, halitosis (bad breath),
immune support, teeth and gum health and skin health. BLIS® products are sold throughout New Zealand
and in Asia, Europe and the USA. More information about Blis Technologies Ltd can be found at
www.blis.co.nz.
Data sourced from publicly available filings. Our datasets may not be complete. Automated analysis can produce errors. If you believe any data on this page is incorrect, please contact us at hello@nzxplorer.co.nz. For informational purposes only. Not investment advice.
Other issuers discussed similar conditions around this time
Matched by meaning across NZX announcement text, not keywords — based on our semantic index of announcement bodies.
- BGP — Briscoe Group Limited: Full Year Results to 29 January 20232023-03-14
“Results announcement Results for announcement to the market Name of issuer BRISCOE GROUP LIMITED Reporting Period Full Year (52 weeks) – 31 January 2022 to 29 January 2023 Previous Reporting Period Full Year (52 weeks) – 1 February 2021 to 30 January 2022 Currency…”
- PEB — Pacific Edge Limited: Financial Results for the Half Year to 30 September 20222022-11-23
“Company Announcement 24 November 2022 FINANCIAL RESULTS FOR THE HALF YEAR TO 30 SEPTEMBER 2022 PACIFIC EDGE INVESTMENT FOR GROWTH DELIVERS EARLY RESULTS HIGHLIGHTS • Operating revenue from test sales increases 62% to $8.7 million when compared to the same period of the…”
- PEB — Pacific Edge Limited: Pacific Edge Full Year Result to be Announced 25 May 20232023-05-01
“Company Announcement 1 May 2023 PACIFIC EDGE FULL YEAR RESULT TO BE ANNOUNCED 25 MAY 2023 Cancer diagnostics company Pacific Edge Limited (NZX:PEB) advises that its full year results for the 12 months to 31 March 2023 (FY23) will be released on Thursday 25 May 2023, prior…”